Transient ischemic attack: Part II. Risk factor modification and treatment.
Interventions following a transient ischemic attack are aimed at preventing a future episode or stroke. Hypertension, current smoking, obesity, physical inactivity, diabetes mellitus, and dyslipidemia are all well-known risk factors, and controlling these factors can have dramatic effects on transient ischemic attack and stroke risk. For patients presenting within 48 hours of resolution of transient ischemic attack symptoms, advantages of hospital admission include rapid diagnostic evaluation and early intervention to reduce the risk of stroke. For long-term prevention of future stroke, the American Heart Association/American Stroke Association recommends antiplatelet agents, statins, and carotid artery intervention for advanced stenosis. Aspirin, extended-release dipyridamole/aspirin, and clopidogrel are acceptable first-line antiplatelet agents. Statins have also been shown to reduce the risk of stroke following transient ischemic attack, with maximal benefit occurring with at least a 50 percent reduction in low-density lipoprotein cholesterol level or a target of less than 70 mg per dL (1.81 mmol per L). For those with transient ischemic attack and carotid artery stenosis, carotid endarterectomy is recommended if stenosis is 70 to 99 percent, and perioperative morbidity and mortality are estimated to be less than 6 percent.
Drexel University College of Medicine, Philadelphia, PA 19127, USA. bsimmons@drexelmed.edu
B Brent
BB
Simmons
Annette B
AB
Gadegbeku
Barbara
B
Cirignano
D000428:Alcohol Drinking / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000627:therapeutic use; D016893:Carotid Stenosis / Q000150:complications / Q000601:surgery; D048909:Diabetes Complications / Q000628:therapy; D003920:Diabetes Mellitus / Q000628:therapy; D050171:Dyslipidemias / Q000150:complications / Q000628:therapy; D016894:Endarterectomy, Carotid; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000628:therapy; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery / Q000628:therapy*; D009765:Obesity / Q000150:complications / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D057185:Sedentary Behavior; D012907:Smoking / Q000009:adverse effects; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors